Enrolling: Bateman-Horne InTime Drug Intervention Trial

The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months.
Who:
Dr. Lucinda Bateman, Located in Salt Lake City, Utah at the Bateman-Horne Institute.

When:

Ongoing


What:

A Clinical Trial for ME/CFS Patients: BHC is conducting a small interventional trial, to test the effectiveness of a new drug that may improve functioning and/or reduce the symptoms in ME/CFS patients. The drug has been shown to be safe in a Phase 1 trial in healthy humans.


Where:

Bateman-Horne Institute, Salt Lake City, Utah


How to Participate:

If you are interested in participating in this trial, please follow the link below and fill out the following form to check for eligibility:
https://redcap01.brisc.utah.edu/ccts/redcap/surveys/?s=MC4EAT4YNE

Facebook
Twitter
WhatsApp
Email

Latest News

Text across top of image reads: "Experts in infection associated chronic illness" with "WE WANT YOU!" bolded below it. Hand with finger pointed out at viewer. "Apply now" buttons to the left and right with mouse cursor clicking on them.

Infection-associated chronic disease experts needed at ARPA-H

Congress launched ARPA-H (the Advanced Research Projects Agency for Health) this past March to focus on high-risk, high-reward research projects with the goal to solve intractable health problems. As ARPA-H is in the process of hiring its first cohort of program managers, #MEAction and a coalition of chronic disease advocacy groups have published an open

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.

Donate

Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Subscribe
Scroll to Top